
Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.

Your AI-Trained Oncology Knowledge Connection!


Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.

Dr Brentjens discussed targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

Eunice Wang, MD, discusses the long-term results of a phase 2 trial investigating crenolanib plus chemotherapy in adult patients with newly diagnosed FLT3-mutant acute myeloid leukemia.

Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

The utilization of monoclonal antibodies such as nivolumab and Ipilimumab have become vital in shifting the treatment paradigm in gastroesophageal and gastrointestinal cancers.

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

Neoadjuvant chemosensitivity was associated with an improvement in overall survival following adjuvant chemotherapy in patients with resectable gastric cancer, according to findings from a cohort study that were published in JAMA Network Open.

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

The combination of tivozanib and durvalumab showcased early efficacy with a manageable safety profile in patients with previously untreated advanced hepatocellular carcinoma.

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.

Dhyan Chandra, PhD, discusses the potential to assess mitochondrial function to inform outcomes in prostate cancer.

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.

New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and eliminating prostate cancer health disparities.

Nathaniel Ivanick, MD, FCCP, discusses the evolution of interventional pulmonology, the benefits of robotic navigational bronchoscopy and other novel technologies in the field, and ongoing research that could further push the paradigm forward.

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

Following a national search, Roswell Park Comprehensive Cancer Center has promoted Emese Zsiros, MD, PhD, FACOG, to lead its Department of Gynecologic Oncology.

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.

Jamie Smith, EdD, MLS, has joined the cancer center as Chief Academic Officer, Senior Vice President of Education and Dean of the Roswell Park Graduate Division of the University at Buffalo.

Driven to move the mission of Roswell Park Comprehensive Cancer Center forward despite the many challenges the COVID-19 pandemic brought with it, Roswell Park President and CEO Candace S. Johnson, PhD, has marked a year of unprecedented success in faculty recruitment

Teams of researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center are combining efforts after together securing a nearly $9 million grant from the National Cancer Institute to develop new and better treatments for ovarian cancer.

Anurag Singh, MD, discussed the potential advantage to treating patients with radiation therapy at specific times of day, how the utilization of prophylactic gabapentin has decreased the need for narcotics in managing oral mucositis in patients with head and neck cancer, and the potential use of single-fraction radiation therapy in oncology.

Anurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.